$6.41
0.111.75%
At close: -
$6.42
0.010000.16%
After Hours: Jun 20, 7:47 PM EDT
Comments
Loading...
Novavax Stock Guidance | NASDAQ:NVAX | Benzinga
Novavax issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 05/08/2025 | NVAX | Novavax | FY | 2025 | — | — | — | $975.00M | $1.02B | — | Get Alert |
| 01/13/2025 | NVAX | Novavax | FY | 2024 | — | — | — | $650.00M | $700.00M | $724.08M | Get Alert |
| 11/12/2024 | NVAX | Novavax | FY | 2024 | — | — | — | $650.00M | $700.00M | $761.46M | Get Alert |
| 08/08/2024 | NVAX | Novavax | FY | 2024 | — | — | — | $700.00M | $800.00M | $936.38M | Get Alert |
| 05/10/2024 | NVAX | Novavax | FY | 2024 | — | — | — | $400.00M | $600.00M | $845.49M | Get Alert |
| 02/28/2024 | NVAX | Novavax | Q1 | 2024 | — | — | — | $100.00M | $100.00M | $292.33M | Get Alert |
| 02/28/2024 | NVAX | Novavax | FY | 2024 | — | — | — | $800.00M | $1.00B | $969.56M | Get Alert |
| 11/09/2023 | NVAX | Novavax | FY | 2023 | — | — | — | $900.00M | $1.10B | $1.35B | Get Alert |
| 11/09/2023 | NVAX | Novavax | Q1 | 2024 | — | — | — | $300.00M | $300.00M | $648.29M | Get Alert |
| 08/08/2023 | NVAX | Novavax | FY | 2023 | — | — | — | $1.30B | $1.50B | $1.44B | Get Alert |
| 05/09/2023 | NVAX | Novavax | FY | 2023 | — | — | — | $1.40B | $1.60B | $831.60M | Get Alert |
| 12/14/2022 | NVAX | Novavax | FY | 2022 | — | — | — | $2.00B | $2.00B | $2.01B | Get Alert |
| 11/08/2022 | NVAX | Novavax | FY | 2022 | — | — | — | $2.00B | $2.00B | $2.04B | Get Alert |
| 08/08/2022 | NVAX | Novavax | FY | 2022 | — | — | — | $2.00B | $2.30B | $4.27B | Get Alert |
| 05/09/2022 | NVAX | Novavax | FY | 2022 | — | — | — | $4.00B | $5.00B | $4.49B | Get Alert |
| 02/28/2022 | NVAX | Novavax | FY | 2022 | — | — | — | $4.00B | $5.00B | $4.70B | Get Alert |
FAQ
What is the most recent guidance for Novavax (NVAX)?
There have been no specific sales or earnings guidance reported for Novavax in recent months.
Browse guidance and forecast on all stocks.
